RCS - Theracryf PLC - Investor Webinar

TheracryfAnnouncement

21/04/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260421:nRSU1826Ba&default-theme=true

RNS Number : 1826B  Theracryf PLC  21 April 2026

 

21 April 2026

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

 

Investor Webinar

TheraCryf plc (AIM: TCF), the biotech company developing new medicines for
addiction and other neuropsychiatric disorders, today announces that Dr Huw
Jones, Chief Executive Officer and Dr Helen Kuhlman, Chief Operating Officer,
will host an investor webinar on Friday, 24 April 2026 at 10.00 am (BST).

 

The webinar will focus on the Company's recent announcements, including
progress in its lead orexin-1 (Ox-1) receptor antagonist programme for
addiction as it moves towards clinical readiness, alongside broader strategic
developments as TheraCryf advances Ox-1 towards first-in-human studies.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
Thursday, 23 April 2026, 9.00 am (BST), or at any time during the live
presentation. Investors can sign up to Investor Meet Company for free and add
to meet TheraCryf via:
https://www.investormeetcompany.com/theracryf-plc/register-investor
(https://www.investormeetcompany.com/theracryf-plc/register-investor)

 

Investors who already follow TheraCryf on the Investor Meet Company platform
will automatically be invited.

 

-Ends-

 

Enquiries

 

 TheraCryf plc                                      +44 (0)1625 315 090

 Dr Huw Jones, CEO                                  enquiries@theracryf.com

 Toni Hänninen, CFO

 Dr Helen Kuhlman, COO

 Singer Capital Markets (NOMAD & Joint Broker)      +44 (0)20 7496 3000
 Phil Davies / Patrick Weaver

 Turner Pope Investments (Joint Broker)             +44 (0)20 3657 0050

 Guy McDougall / Andy Thacker

 Northstar Communications (Investor Relations)      +44 (0)113 730 3896

 Sarah Hollins                                      sarah@northstarcommunications.co.uk
                                                    (mailto:sarah@northstarcommunications.co.uk)

 

About TheraCryf

 

TheraCryf plc is a biotechnology company developing new medicines for
addiction and other neuropsychiatric disorders, areas of significant unmet
medical need within central nervous system (CNS) disorders.

 

The Group's lead programme is a novel, best-in-class orexin-1 receptor
antagonist being developed as a potential treatment for addiction, including
binge eating, alcohol and other substance use disorders.

The programme has already been heavily de-risked for both safety/tolerability
and efficacy in previous testing and is fully funded through final
pre-clinical trials to clinical readiness, with regulatory submissions for
first in man studies targeted for 2026.

 

TheraCryf also has a dopamine transporter (DAT) modulator programme addressing
fatigue of brain origin, including fatigue associated with multiple sclerosis,
chemotherapy and narcolepsy. The Group also has a legacy, grant-funded,
oncology programme in glioblastoma with SFX-01.

 

The Group operates a capital-light, virtual development model advancing
programmes to early clinical or proof-of-concept stage before partnering with
commercially focused pharmaceutical and biotechnology companies.

 

TheraCryf's headquarters and registered office are at Alderley Park, Cheshire.

 

For further information, visit: https://theracryf.com (https://theracryf.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEALLEALEKEFA



            Copyright 2019 Regulatory News Service, all rights reserved